Dayna Johnson, PhD, MPH, MSW, MS talks about the necessity of community partnerships as the recipient of this year’s Associated Professional Sleep Societies (APSS) Diversity, Equity, and Inclusion Leadership Award at SLEEP 2023 and how inquiring into the community is vital for integrating healthy sleep practices.
Understanding what the community needs when committing to diversity, equity, and inclusion efforts is an integral part to helping communities’ improve their sleep health, explains Dayna Johnson, PhD, MPH, MSW, MS, assistant professor of epidemiology at the Rollins School of Public Health at Emory University in this interview from SLEEP 2023.
Transcript
How important are community partnerships to diversity, equity, and inclusion efforts?
They're absolutely essential. Without community partnerships, we can't do this work. Something that I like to talk a lot about is the lived experience. What we're doing in this research is really informed by what's a priority to the community, and then what's feasible. It's one thing for us to come up with different ways on how to intervene, but if someone is not amenable to those, then it won't be efficient or effective. So, having those partnerships to find out, “what's the priority? How can we partner to make this change?” And then also for us to understand, “what are the factors that are prohibiting sleep for you?”
As an example, from some of my work, we did focus groups around what we formerly referred to as sleep hygiene, which is really just healthy sleep practices, which include sleeping in a dark, quiet room. We had participants say, "I absolutely can't do that. Someone will break into my house if it's dark." That's not something whoever created these thought about. There's nothing around safety, but it's absolutely important. We have to make sure we're finding out, what are the barriers and facilitators and then using those to leverage the work we're doing to make change.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More